LXR is a nuclear hormone receptor that is highly expressed in the epidermis and LXR modulators target multiple aspects of skin disease pathology associated with immunologic, inflammatory and barrier dysfunction. ALX-101 is a proprietary soft drug formulation designed to minimize systemic absorption and thereby avoid systemic side effects. An initial phase 1/2A study completed in Q3 2016, supported the soft drug hypothesis and provides the foundation to progress into Phase 2B. The Company will be initiating a phase 2B study of ALX-101 in the treatment of atopic dermatitis in the first quarter of 2017.
In addition to dermatology indications, Ralexar Therapeutics is also pursuing additional non-dermal indications with its portfolio of LXR compounds.